Oriol Martin-Segarra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Oriol Martin-Segarra has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Amir Shabaka
Nephrology Department, Hospital Universitario La Paz, Madrid, Spain
1 shared publication - Ana González Moreno
Allergy Unit Hospital Universitario Fundación Alcorcón Madrid Spain
1 shared publication - Ana Rosado
Unidad de Alergia, Hospital Universitario Fundación Alcorcón, Madrid, Spain
1 shared publication - Andrea M. Gonzalez-Lopez
University Hospital Foundation Alcorcon, 28922 Alcorcon, Madrid, Spain
1 shared publication - Antonio Gil-Crujera
Department of Basic Health Sciences Rey Juan Carlos University Madrid Spain
1 shared publication Clara Cases-Corona
Nephrology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 5 August 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2543520
Real-world experience of barriers to diagnosis, early detection and disease management among migrants living with HIV in Spain: a qualitative study
To describe the barriers and challenges in the medical care management of a group of migrants living with HIV who received medical assistance through the Spanish Public Health Care Services. A qualitative descriptive study was conducted. The inclusion criteria comprised patients with a confirmed serological diagnosis of HIV whose countries of origin were in Latin America, the Caribbean, Africa, or Eastern Europe. A total of 21 patients were selected through purposive sampling. Data collection involved in-depth interviews and researcher field notes. A thematic analysis was performed, and trustworthiness criteria were applied. Two themes were identified that illustrate the barriers to healthcare in migrants living with HIV: a) Personal beliefs and the social and family environment, participants often remain in contact with members of their culture and/or ethnic group of origin, and their environment can hinder help-seeking, treatment adherence, or open communication about their illness; b) The healthcare environment, where obstacles and challenges faced by participants are described in relation to the healthcare environment, the healthcare system, and healthcare providers. The results of this study provide a foundation for developing a roadmap of relevant patient-reported outcomes in HIV care. These insights can guide the implementation of improved healthcare strategies for migrants living with HIV.
- 5 August 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2543520
Open AccessReal-world experience of barriers to diagnosis, early detection and disease management among migrants living with HIV in Spain: a qualitative study
To describe the barriers and challenges in the medical care management of a group of migrants living with HIV who received medical assistance through the Spanish Public Health Care Services. A qualitative descriptive study was conducted. The inclusion criteria comprised patients with a confirmed serological diagnosis of HIV whose countries of origin were in Latin America, the Caribbean, Africa, or Eastern Europe. A total of 21 patients were selected through purposive sampling. Data collection involved in-depth interviews and researcher field notes. A thematic analysis was performed, and trustworthiness criteria were applied. Two themes were identified that illustrate the barriers to healthcare in migrants living with HIV: a) Personal beliefs and the social and family environment, participants often remain in contact with members of their culture and/or ethnic group of origin, and their environment can hinder help-seeking, treatment adherence, or open communication about their illness; b) The healthcare environment, where obstacles and challenges faced by participants are described in relation to the healthcare environment, the healthcare system, and healthcare providers. The results of this study provide a foundation for developing a roadmap of relevant patient-reported outcomes in HIV care. These insights can guide the implementation of improved healthcare strategies for migrants living with HIV.
- 5 September 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (12) , 1314-1317
Integration of beta‐lactam allergy evaluation in a Spanish antibiotic stewardship programme
- 5 September 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (12) , 1314-1317
Integration of beta‐lactam allergy evaluation in a Spanish antibiotic stewardship programme
- 28 April 2020
- Published by S. Karger AG in Nephron
- Vol. 144 (6) , 304-309
Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft
Emphysematous pyelonephritis (EPN) is a rare and serious necrotizing infection that is potentially life-threatening. It has been seldom reported in kidney grafts and is usually caused by Gram-negative bacteria, with some case reports caused by anaerobic bacteria, and has been closely associated with poorly controlled diabetes mellitus (DM) and urinary tract structural abnormalities. There are no reports of EPN of fungal etiology in kidney grafts. We present a case of a 53-year-old kidney transplant recipient with a history of DM, active vesicoureteral reflux, and recurrent urinary tract infections who developed EPN in the kidney allograft caused by Candida glabrata, 3 weeks after starting treatment with empagliflozin, with an aggressive course that required urgent transplant nephrectomy.
- 28 April 2020
- Published by S. Karger AG in Nephron
- Vol. 144 (6) , 304-309
Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft
Emphysematous pyelonephritis (EPN) is a rare and serious necrotizing infection that is potentially life-threatening. It has been seldom reported in kidney grafts and is usually caused by Gram-negative bacteria, with some case reports caused by anaerobic bacteria, and has been closely associated with poorly controlled diabetes mellitus (DM) and urinary tract structural abnormalities. There are no reports of EPN of fungal etiology in kidney grafts. We present a case of a 53-year-old kidney transplant recipient with a history of DM, active vesicoureteral reflux, and recurrent urinary tract infections who developed EPN in the kidney allograft caused by Candida glabrata, 3 weeks after starting treatment with empagliflozin, with an aggressive course that required urgent transplant nephrectomy.